{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:29:26Z","timestamp":1791336566333,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HU20C0271"],"award-info":[{"award-number":["HU20C0271"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Research Foundation of Korea,South Korea","award":["NRF-2021R1A2C1093636"],"award-info":[{"award-number":["NRF-2021R1A2C1093636"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68916-4","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:25:29Z","timestamp":1723191929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Elevated cerebral blood flow proxy with increased beta-amyloid burden in Alzheimer\u2019s disease preclinical phase evaluated by dual-phase 18F-florbetaben positron emission tomography"],"prefix":"10.1038","volume":"14","author":[{"given":"Geon Ha","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bori R.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Jeon","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"68916_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2018.02.001","volume":"14","author":"A Association","year":"2018","unstructured":"Association, A. 2018 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 14, 367\u2013429 (2018).","journal-title":"Alzheimers Dement."},{"key":"68916_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack, C. R. et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 9, 119\u2013128 (2010).","journal-title":"Lancet Neurol."},{"key":"68916_CR3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 370, 322\u2013333 (2014).","journal-title":"N. Engl. J. Med."},{"key":"68916_CR4","first-page":"2470","volume":"319","author":"A Slomski","year":"2018","unstructured":"Slomski, A. A\u03b2-clearing drug fails to slow alzheimer disease. Jama 319, 2470\u20132470 (2018).","journal-title":"Jama"},{"key":"68916_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimer's Dement."},{"key":"68916_CR6","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1212\/WNL.0b013e3181bc010c","volume":"73","author":"WJ Jagust","year":"2009","unstructured":"Jagust, W. J. et al. Relationships between biomarkers in aging and dementia. Neurology 73, 1193\u20131199 (2009).","journal-title":"Neurology"},{"key":"68916_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.neurobiolaging.2013.09.028","volume":"35","author":"SC Johnson","year":"2014","unstructured":"Johnson, S. C. et al. Amyloid burden and neural function in people at risk for Alzheimer\u2019s Disease. Neurobiol. Aging 35, 576\u2013584 (2014).","journal-title":"Neurobiol. Aging"},{"key":"68916_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaneurol.2013.182","volume":"70","author":"DS Knopman","year":"2013","unstructured":"Knopman, D. S. et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with \u03b2-amyloidosis. JAMA Neurol. 70, 1030\u20131038 (2013).","journal-title":"JAMA Neurol."},{"key":"68916_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/hbm.22173","volume":"35","author":"H Oh","year":"2014","unstructured":"Oh, H., Habeck, C., Madison, C. & Jagust, W. Covarying alterations in A\u03b2 deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp. 35, 297\u2013308 (2014).","journal-title":"Hum. Brain Mapp."},{"key":"68916_CR10","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.2967\/jnumed.108.051946","volume":"49","author":"J Sojkova","year":"2008","unstructured":"Sojkova, J. et al. Longitudinal cerebral blood flow and amyloid deposition: An emerging pattern?. J. Nucl. Med. 49, 1465\u20131471 (2008).","journal-title":"J. Nucl. Med."},{"key":"68916_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/jmri.26810","volume":"51","author":"A Fazlollahi","year":"2020","unstructured":"Fazlollahi, A. et al. Increased cerebral blood flow with increased amyloid burden in the preclinical phase of alzheimer\u2019s disease. J. Magn. Reson. Imaging 51, 505\u2013513 (2020).","journal-title":"J. Magn. Reson. Imaging"},{"key":"68916_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1177\/0271678X15605847","volume":"36","author":"L Michels","year":"2016","unstructured":"Michels, L. et al. Arterial spin labeling imaging reveals widespread and A\u03b2-independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers. J. Cereb. Blood Flow Metab. 36, 581\u2013595 (2016).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"68916_CR13","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack","year":"2013","unstructured":"Jack, C. R. et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207\u2013216 (2013).","journal-title":"Lancet Neurol."},{"key":"68916_CR14","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1148\/radiol.2018170575","volume":"288","author":"I Riederer","year":"2018","unstructured":"Riederer, I. et al. Alzheimer disease and mild cognitive impairment: Integrated pulsed arterial spin-labeling MRI and 18F-FDG PET. Radiology 288, 198\u2013206 (2018).","journal-title":"Radiology"},{"key":"68916_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00401-020-02215-w","volume":"140","author":"N Korte","year":"2020","unstructured":"Korte, N., Nortley, R. & Attwell, D. Cerebral blood flow decrease as an early pathological mechanism in Alzheimer\u2019s disease. Acta Neuropathol. 140, 793\u2013810 (2020).","journal-title":"Acta Neuropathol."},{"key":"68916_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic, B. V. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat. Rev. Neurosci. 12, 723\u2013738 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"68916_CR17","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1177\/0271678X231178993","volume":"43","author":"BE Padrela","year":"2023","unstructured":"Padrela, B. E. et al. Genetic, vascular and amyloid components of cerebral blood flow in a preclinical population. J. Cereb. Blood Flow Metab. 43, 1726\u20131736 (2023).","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"68916_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jalz.2019.05.010","volume":"15","author":"J Ottoy","year":"2019","unstructured":"Ottoy, J. et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer\u2019s disease: Validation against 15O\u2013H2O PET. Alzheimer\u2019s & Dement. 15, 1172\u20131182 (2019).","journal-title":"Alzheimer's & Dement."},{"key":"68916_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211000","volume":"14","author":"DE Peretti","year":"2019","unstructured":"Peretti, D. E. et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer\u2019s disease PET studies. PloS One 14, e0211000 (2019).","journal-title":"PloS One"},{"key":"68916_CR20","doi-asserted-by":"publisher","first-page":"102773","DOI":"10.1016\/j.nicl.2021.102773","volume":"31","author":"H-J Yoon","year":"2021","unstructured":"Yoon, H.-J. et al. Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer\u2019s disease. NeuroImage Clin. 31, 102773 (2021).","journal-title":"NeuroImage Clin."},{"key":"68916_CR21","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/alz.12069","volume":"16","author":"I Lopes Alves","year":"2020","unstructured":"Lopes Alves, I. et al. Quantitative amyloid PET in Alzheimer\u2019s disease: The AMYPAD prognostic and natural history study. Alzheimer\u2019s & Dement. 16, 750\u2013758 (2020).","journal-title":"Alzheimer's & Dement."},{"key":"68916_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/380168a0","volume":"380","author":"T Thomas","year":"1996","unstructured":"Thomas, T., Thomas, G., McLendon, C., Sutton, T. & Mullan, M. \u03b2-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380, 168\u2013171 (1996).","journal-title":"Nature"},{"key":"68916_CR23","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5715","volume":"2","author":"C Iadecola","year":"1999","unstructured":"Iadecola, C. et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci. 2, 157\u2013161 (1999).","journal-title":"Nat. Neurosci."},{"key":"68916_CR24","doi-asserted-by":"publisher","first-page":"9735","DOI":"10.1073\/pnas.97.17.9735","volume":"97","author":"K Niwa","year":"2000","unstructured":"Niwa, K. et al. A\u03b21\u201340-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. 97, 9735\u20139740 (2000).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"68916_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/ncb1819","volume":"11","author":"RD Bell","year":"2009","unstructured":"Bell, R. D. et al. SRF and myocardin regulate LRP-mediated amyloid-\u03b2 clearance in brain vascular cells. Nat. Cell Biol. 11, 143\u2013153 (2009).","journal-title":"Nat. Cell Biol."},{"key":"68916_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1073\/pnas.0608251104","volume":"104","author":"N Chow","year":"2007","unstructured":"Chow, N. et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer\u2019s phenotype. Proc. Natl. Acad. Sci. 104, 823\u2013828 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"68916_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.629442","volume":"12","author":"R Ferrando","year":"2021","unstructured":"Ferrando, R. & Damian, A. Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging: Still a valid option?. Front. Neurol. 12, 629442 (2021).","journal-title":"Front. Neurol."},{"key":"68916_CR28","first-page":"76","volume":"9","author":"JF Leijenaar","year":"2017","unstructured":"Leijenaar, J. F. et al. Lower cerebral blood flow in subjects with Alzheimer\u2019s dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit. 9, 76\u201383 (2017).","journal-title":"Alzheimer's Dement. Diagn. Assess. Dis. Monit."},{"key":"68916_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1148\/radiol.2503080751","volume":"250","author":"W Dai","year":"2009","unstructured":"Dai, W. et al. Mild cognitive impairment and alzheimer disease: Patterns of altered cerebral blood flow at MR imaging. Radiology 250, 856\u2013866 (2009).","journal-title":"Radiology"},{"key":"68916_CR30","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3233\/JAD-132252","volume":"41","author":"ZZ Zlatar","year":"2014","unstructured":"Zlatar, Z. Z., Wierenga, C. E., Bangen, K. J., Liu, T. T. & Jak, A. J. Increased hippocampal blood flow in sedentary older adults at genetic risk for Alzheimer\u2019s disease. J. Alzheimer\u2019s Dis. 41, 809\u2013817 (2014).","journal-title":"J. Alzheimer's Dis."},{"key":"68916_CR31","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.3233\/JAD-2012-120292","volume":"31","author":"KJ Bangen","year":"2012","unstructured":"Bangen, K. J. et al. Assessment of Alzheimer\u2019s disease risk with functional magnetic resonance imaging: An arterial spin labeling study. J. Alzheimer\u2019s Dis. 31, S59\u2013S74 (2012).","journal-title":"J. Alzheimer's Dis."},{"key":"68916_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.neuron.2009.07.003","volume":"63","author":"RA Sperling","year":"2009","unstructured":"Sperling, R. A. et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 63, 178\u2013188 (2009).","journal-title":"Neuron"},{"key":"68916_CR33","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/cercor\/bhr255","volume":"22","author":"EC Mormino","year":"2012","unstructured":"Mormino, E. C. et al. A\u03b2 deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb. Cortex 22, 1813\u20131823 (2012).","journal-title":"Cereb. Cortex"},{"key":"68916_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s00330-015-3834-9","volume":"26","author":"MA Binnewijzend","year":"2016","unstructured":"Binnewijzend, M. A. et al. Cerebral perfusion in the predementia stages of Alzheimer\u2019s disease. Eur. Radiol. 26, 506\u2013514 (2016).","journal-title":"Eur. Radiol."},{"key":"68916_CR35","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00259-016-3353-1","volume":"43","author":"S Tiepolt","year":"2016","unstructured":"Tiepolt, S. et al. Early [18F] florbetaben and [11C] PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer\u2019s disease. Eur. J. Nucl. Med. Mol. Imaging 43, 1700\u20131709 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"68916_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.2967\/jnumed.117.200964","volume":"59","author":"S Bullich","year":"2018","unstructured":"Bullich, S. et al. Validation of noninvasive tracer kinetic analysis of 18F-florbetaben PET using a dual\u2013time-window acquisition protocol. J. Nucl. Med. 59, 1104\u20131110 (2018).","journal-title":"J. Nucl. Med."},{"key":"68916_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13550-019-0499-4","volume":"9","author":"F Heeman","year":"2019","unstructured":"Heeman, F. et al. Optimized dual-time-window protocols for quantitative [18F] flutemetamol and [18F] florbetaben PET studies. EJNMMI Res. 9, 1\u201314 (2019).","journal-title":"EJNMMI Res."},{"key":"68916_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.bbadis.2011.11.006","volume":"1822","author":"A Forsberg","year":"2012","unstructured":"Forsberg, A., Engler, H., Blomquist, G., L\u00e5ngstr\u00f6m, B. & Nordberg, A. The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis. 1822, 380\u2013385 (2012).","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"68916_CR39","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1007\/s00259-016-3359-8","volume":"43","author":"K-J Lin","year":"2016","unstructured":"Lin, K.-J. et al. Imaging characteristic of dual-phase 18F-florbetapir (AV-45\/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer\u2019s disease and mild cognitive impairment. Eur. J. Nucl. Med. Mol. Imaging 43, 1304\u20131314 (2016).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"68916_CR40","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"BN van Berckel","year":"2013","unstructured":"van Berckel, B. N. et al. Longitudinal amyloid imaging using 11C-PiB: Methodologic considerations. J. Nucl. Med. 54, 1570\u20131576 (2013).","journal-title":"J. Nucl. Med."},{"key":"68916_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.2967\/jnumed.116.184481","volume":"58","author":"J Ottoy","year":"2017","unstructured":"Ottoy, J. et al. Validation of the semiquantitative static SUVR method for 18F-AV45 PET by pharmacokinetic modeling with an arterial input function. J. Nucl. Med. 58, 1483\u20131489 (2017).","journal-title":"J. Nucl. Med."},{"key":"68916_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse, S. K. et al. Validation of amyloid PET positivity thresholds in centiloids: A multisite PET study approach. Alzheimer\u2019s Res. Ther. 13, 99 (2021).","journal-title":"Alzheimer's Res. Ther."},{"key":"68916_CR43","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. et al. The AHEAD 3\u201345 study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 19, 1227\u20131233 (2023).","journal-title":"Alzheimer's Dement."},{"key":"68916_CR44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2967\/jnumed.110.083683","volume":"52","author":"PT Meyer","year":"2011","unstructured":"Meyer, P. T. et al. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J. Nucl. Med. 52, 393\u2013400 (2011).","journal-title":"J. Nucl. Med."},{"key":"68916_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12779\/dnd.2023.22.1.1","volume":"22","author":"HJ Ryu","year":"2023","unstructured":"Ryu, H. J. & Yang, D. W. The Seoul neuropsychological screening battery (SNSB) for comprehensive neuropsychological assessment. Dement. Neurocogn. Disord. 22, 1 (2023).","journal-title":"Dement. Neurocogn. Disord."},{"key":"68916_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163792","volume":"11","author":"MJ Baek","year":"2016","unstructured":"Baek, M. J., Kim, K., Park, Y. H. & Kim, S. The validity and reliability of the mini-mental state examination-2 for detecting mild cognitive impairment and Alzheimer\u2019s disease in a Korean population. PloS One 11, e0163792 (2016).","journal-title":"PloS One"},{"key":"68916_CR47","unstructured":"Choi, S. -H. et al. Estimating the validity of the Korean version of expanded clinical dementia rating (CDR) scale. J. Korean Neurol. Assoc. 585\u2013591 (2001)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68916-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68916-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68916-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:30:40Z","timestamp":1723192240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68916-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68916"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68916-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"11 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18480"}}